Published in J Infect Dis on June 01, 1999
Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol (2008) 3.83
Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics. PLoS Comput Biol (2007) 2.25
Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol (2009) 2.16
Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol (2008) 2.16
Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol (2008) 1.80
The Antibody Response against HIV-1. Cold Spring Harb Perspect Med (2012) 1.65
Frequent toggling between alternative amino acids is driven by selection in HIV-1. PLoS Pathog (2008) 1.49
Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J Virol (2001) 1.25
Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology (2013) 1.19
Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains. J Virol (2005) 1.14
Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J Virol (2005) 1.12
Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope. Virology (2007) 1.07
Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood (2006) 1.03
Viral exploitation of host SOCS protein functions. J Virol (2010) 1.01
Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques. J Virol (2003) 0.94
Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance. J Med Primatol (2006) 0.90
Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients. PLoS Pathog (2015) 0.89
Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J Acquir Immune Defic Syndr (2011) 0.88
Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120. J Virol (2001) 0.88
Increased neutralization sensitivity and reduced replicative capacity of human immunodeficiency virus type 1 after short-term in vivo or in vitro passage through chimpanzees. J Virol (2000) 0.81
Genetic variation and HIV-associated neurologic disease. Adv Virus Res (2013) 0.81
Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy. PLoS Pathog (2010) 0.80
B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses. PLoS One (2011) 0.76
Effects of neutralizing antibodies on escape from CD8+ T-cell responses in HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2015) 0.76
Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines. Viruses (2014) 0.75
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49
The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature (1987) 7.06
The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med (1990) 6.94
Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 5.30
Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med (1982) 4.98
Changes in T and non-T lymphocyte subsets following seroconversion to HIV-1: stable CD3+ and declining CD3- populations suggest regulatory responses linked to loss of CD4 lymphocytes. The Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (1993) 4.92
The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med (1992) 4.88
Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science (1983) 4.72
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 4.72
The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med (1990) 4.25
Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J Virol (1989) 4.07
Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol (1991) 3.93
Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis (2000) 3.73
HIV-associated neurologic disease incidence changes:: Multicenter AIDS Cohort Study, 1990-1998. Neurology (2001) 3.55
Glomerular filtration rate via plasma iohexol disappearance: pilot study for chronic kidney disease in children. Kidney Int (2006) 3.48
Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nat Med (1995) 3.46
Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol (2001) 3.44
Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol (1993) 3.39
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol (1994) 3.33
Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis (1992) 3.27
Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma. J Infect Dis (2000) 3.20
Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 3.07
Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection. JAMA (1992) 3.07
Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology (1995) 3.06
Frozen section analysis for intraoperative margin assessment during breast-conserving surgery results in low rates of re-excision and local recurrence. Ann Surg Oncol (2007) 3.04
Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS (2000) 2.99
Conversion of logarithmic channel numbers into relative linear fluorescence intensity. Cytometry (1988) 2.96
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol (1994) 2.96
Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS (1996) 2.95
Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1991) 2.85
Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol (1998) 2.83
Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product. Nature (1989) 2.78
Immunologic abnormalities in homosexual men. Relationship to Kaposi's sarcoma. Am J Med (1982) 2.71
Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene (2006) 2.69
A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. Cytometry (1991) 2.60
Prevalence of antibody to HIV-1 among entrants to US correctional facilities. JAMA (1991) 2.51
CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 2.45
A retrospective cohort study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1988) 2.38
Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS (1998) 2.33
v-erbA oncogene activation entails the loss of hormone-dependent regulator activity of c-erbA. Cell (1990) 2.31
Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry (1992) 2.19
Longitudinal study of the effects of maternal smoking on pulmonary function in children. N Engl J Med (1983) 2.19
Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr (2000) 2.13
Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med (1995) 2.12
Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol (1987) 2.11
Viability and recovery of peripheral blood mononuclear cells cryopreserved for up to 12 years in a multicenter study. Clin Diagn Lab Immunol (1999) 2.11
Generation of functional thymocytes in the human adult. Immunity (1999) 2.10
CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr (1989) 2.10
Temporal trends of incident human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, Md. Arch Intern Med (1995) 2.08
A case-control study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1987) 2.07
Evaluation of a dual-color flow cytometry immunophenotyping panel in a multicenter quality assurance program. Cytometry (1993) 2.07
Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol (1991) 2.00
Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery. A multicenter study of HIV-1 and HTLV-I/II infections. Ann Intern Med (1992) 1.99
A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. J Immunol Methods (1994) 1.98
Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol (1993) 1.98
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol (1999) 1.97
Temporal trends of human immunodeficiency virus type 1 (HIV-1) infection among inmates entering a statewide prison system, 1985-1987. J Acquir Immune Defic Syndr (1989) 1.96
Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol (2000) 1.96
Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res Hum Retroviruses (1992) 1.94
The multicenter AIDS Cohort Study, 1983 to …. Public Health (2011) 1.93
Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst (1999) 1.92
Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J Immunol (1997) 1.89
Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology (1994) 1.88
Early effects of HIV on CD4 lymphocytes in vivo. J Immunol (1987) 1.87
Pathogenesis of simian immunodeficiency virus encephalitis: viral determinants of neurovirulence. J Virol (1997) 1.86
Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS (2001) 1.84
Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS (2001) 1.79
Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol (2000) 1.78
A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend (1999) 1.78
Antibody to hepatitis C virus among cardiac surgery patients, homosexual men, and intravenous drug users in Baltimore, Maryland. Am J Epidemiol (1991) 1.76
Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol (1998) 1.75
Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev (1997) 1.75
Automobile accidents in patients with sleep apnea syndrome. An epidemiological and mechanistic study. Am J Respir Crit Care Med (1998) 1.74
Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J (1999) 1.73
Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol (1990) 1.68
Transmission of retroviruses by transfusion of screened blood in patients undergoing cardiac surgery. N Engl J Med (1989) 1.67
Methods for quantitative and qualitative evaluation of vaginal microflora during menstruation. Appl Environ Microbiol (1986) 1.67
Influence of HIV-1 infection and cigarette smoking on leukocyte profiles in homosexual men. The Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (1992) 1.66
Estimating the distribution of times from HIV seroconversion to AIDS using multiple imputation. Multicentre AIDS Cohort Study. Stat Med (1990) 1.65
Effect of CD4+ cell count measurement variability on staging HIV-1 infection. J Acquir Immune Defic Syndr (1992) 1.65
Association of drug injection patterns with antibody to human immunodeficiency virus type 1 among intravenous drug users in Baltimore, Maryland. Am J Epidemiol (1990) 1.65
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Pathogenesis of SIV encephalitis. Selection and replication of neurovirulent SIV. Am J Pathol (1997) 1.63
Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med (1997) 1.62
Sensitive method for measuring apoptosis and cell surface phenotype in human thymocytes by flow cytometry. Cytometry (1994) 1.60
Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology (1993) 1.60
Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol (1997) 1.59
Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol (1994) 1.57
Acquired immune deficiency syndrome occurring within 5 years of infection with human immunodeficiency virus type-1: the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (1992) 1.57